These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 24965104)
41. Referral patterns and no-show rates at an outpatient pediatric allergy/immunology clinic. Strothman K; Scherzer R; Phillips G; Stukus DR Ann Allergy Asthma Immunol; 2015 Jun; 114(6):529-30. PubMed ID: 25900019 [No Abstract] [Full Text] [Related]
42. [A Meta-analysis of efficacy and safety of sublingual immunotherapy on allergic asthma]. Wu YY; Xie XM; Han D; Li SJ; Liu L; Li MX Zhonghua Nei Ke Za Zhi; 2013 Oct; 52(10):844-8. PubMed ID: 24378062 [TBL] [Abstract][Full Text] [Related]
43. Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach. Savi E; Peveri S; Senna G; Passalacqua G Allergy; 2013 Sep; 68(9):1193-5. PubMed ID: 23915164 [TBL] [Abstract][Full Text] [Related]
44. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial. Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432 [TBL] [Abstract][Full Text] [Related]
45. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Wang L; Yin J; Fadel R; Montagut A; de Beaumont O; Devillier P Allergy; 2014 Sep; 69(9):1181-8. PubMed ID: 25056584 [TBL] [Abstract][Full Text] [Related]
46. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year). Passalacqua G; Musarra A; Pecora S; Amoroso S; Antonicelli L; Cadario G; Di Gioacchino M; Lombardi C; Ridolo E; Sacerdoti G; Schiavino D; Senna G Pediatr Allergy Immunol; 2007 Feb; 18(1):58-62. PubMed ID: 17295800 [TBL] [Abstract][Full Text] [Related]
47. Quality of life, when to step down asthma therapy and remembering allergic rhinitis. Roberts G Clin Exp Allergy; 2017 Apr; 47(4):440-441. PubMed ID: 28370598 [No Abstract] [Full Text] [Related]
48. Oral/sublingual Phleum pretense grass tablet (Grazax/Grastek) to treat allergic rhinitis in the USA. Nelson HS Expert Rev Clin Immunol; 2014 Nov; 10(11):1437-51. PubMed ID: 25340426 [TBL] [Abstract][Full Text] [Related]
50. [Clinical efficacy and safety of sublingual immunotherapy using standardized Dermatophagoides farinae extract for children with combined allergic rhinitis and asthma syndrome]. Wen CJ; Zhu MF; Ren WM; Liu XY; Qian H Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 May; 46(5):393-6. PubMed ID: 21781561 [TBL] [Abstract][Full Text] [Related]
51. Monoallergen sublingual immunotherapy versus multiallergen subcutaneous immunotherapy for allergic respiratory diseases: a debate during the AAAAI 2013 Annual Meeting in San Antonio, Texas. Calderon MA; Cox LS J Allergy Clin Immunol Pract; 2014; 2(2):136-43. PubMed ID: 24607039 [No Abstract] [Full Text] [Related]
52. Selection of patients for sublingual versus subcutaneous immunotherapy. Larenas Linnemann DE; Blaiss MS Immunotherapy; 2014; 6(7):871-84. PubMed ID: 25290418 [TBL] [Abstract][Full Text] [Related]
53. Sublingual immunotherapy and influence on urinary leukotrienes in seasonal pediatric allergy. Yuksel H; Tanac R; Gousseinov A; Demir E J Investig Allergol Clin Immunol; 1999; 9(5):305-13. PubMed ID: 10582199 [TBL] [Abstract][Full Text] [Related]
54. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Didier A; Wahn U; Horak F; Cox LS Expert Rev Clin Immunol; 2014 Oct; 10(10):1309-24. PubMed ID: 25205329 [TBL] [Abstract][Full Text] [Related]
55. Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children's real life. De Castro G; Zicari AM; Indinnimeo L; Tancredi G; di Coste A; Occasi F; Castagna G; Giancane G; Duse M Eur Rev Med Pharmacol Sci; 2013 Aug; 17(16):2225-31. PubMed ID: 23893190 [TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of sublingual immunotherapy for two seasons in patients with Japanese cedar pollinosis. Okamoto Y; Okubo K; Yonekura S; Hashiguchi K; Goto M; Otsuka T; Murata T; Nakao Y; Kanazawa C; Nagakura H; Okawa T; Nakano K; Hisamitsu M; Kaneko S; Konno A Int Arch Allergy Immunol; 2015; 166(3):177-88. PubMed ID: 25895909 [TBL] [Abstract][Full Text] [Related]
58. Safety and tolerability of sublingual immunotherapy in clinical trials and real life. Senna G; Caminati M; Canonica GW Curr Opin Allergy Clin Immunol; 2013 Dec; 13(6):656-62. PubMed ID: 24126613 [TBL] [Abstract][Full Text] [Related]
59. [Compliance analysis of sublingual immunotherapy and countermeasures]. Chen J; Kong W; Xiang J; Lu Z; Zhou Y Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Mar; 24(5):203-6. PubMed ID: 20464985 [TBL] [Abstract][Full Text] [Related]
60. The role of nasal endoscopy in the prescription of allergen immunotherapy. Schiappoli M; Dama AR; Passalacqua G; Le Pera C; Senna G Eur Ann Allergy Clin Immunol; 2013 Aug; 45(4):150-1. PubMed ID: 24067342 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]